Shares of Xencor, Inc. (NASDAQ:XNCR) have earned a consensus rating of “Hold” from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $30.80.

Several brokerages recently issued reports on XNCR. ValuEngine raised Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Canaccord Genuity set a $36.00 price objective on Xencor and gave the stock a “buy” rating in a report on Monday, October 23rd. Zacks Investment Research cut Xencor from a “hold” rating to a “sell” rating in a report on Saturday, November 11th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 price objective on shares of Xencor in a report on Sunday, November 12th. Finally, Cantor Fitzgerald began coverage on Xencor in a report on Wednesday, November 29th. They set an “overweight” rating and a $33.00 price objective for the company.

In other Xencor news, major shareholder John S. Stafford III acquired 9,215 shares of the stock in a transaction dated Thursday, December 14th. The stock was acquired at an average price of $20.76 per share, with a total value of $191,303.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder John S. Stafford III acquired 24,653 shares of the stock in a transaction dated Wednesday, October 25th. The stock was acquired at an average cost of $20.01 per share, with a total value of $493,306.53. The disclosure for this purchase can be found here. Insiders have acquired 278,535 shares of company stock valued at $5,526,936 in the last three months. 4.03% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in XNCR. FMR LLC grew its position in shares of Xencor by 77.7% in the second quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock valued at $141,232,000 after purchasing an additional 2,924,510 shares during the period. State Street Corp grew its position in shares of Xencor by 11.1% in the second quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock valued at $23,295,000 after purchasing an additional 110,474 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Xencor by 57.4% in the first quarter. Dimensional Fund Advisors LP now owns 286,894 shares of the biopharmaceutical company’s stock valued at $6,863,000 after purchasing an additional 104,638 shares during the period. Artal Group S.A. purchased a new stake in shares of Xencor in the third quarter valued at $2,292,000. Finally, JPMorgan Chase & Co. grew its position in shares of Xencor by 48.1% in the second quarter. JPMorgan Chase & Co. now owns 289,500 shares of the biopharmaceutical company’s stock valued at $6,112,000 after purchasing an additional 93,975 shares during the period. 77.50% of the stock is owned by institutional investors and hedge funds.

Shares of Xencor (XNCR) opened at $22.27 on Friday. Xencor has a 1-year low of $18.55 and a 1-year high of $28.64.

TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/22/xencor-inc-xncr-receives-consensus-rating-of-hold-from-analysts.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.